Bristol-Myers Squibb (BMY) Q3 2024 Earnings
Bristol-Myers Squibb reported Q3 2024 revenue of $11.9B, beat analyst consensus of $11.3B by $627.5M. Diluted EPS came in at $1.80, beat the $1.49 consensus by $0.31. Bristol-Myers Squibb reports across 1 business segment, led by Biopharmaceuticals.
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Bristol-Myers Squibb's Q3 2024 earnings report.
Bristol-Myers Squibb (BMY) reported Q3 2024 earnings on October 31, 2024 before market open.
Bristol-Myers Squibb reported revenue of $11.9B and diluted EPS of $1.80 for Q3 2024.
Revenue beat the consensus estimate of $11.3B by $627.5M. EPS beat the consensus estimate of $1.49 by $0.31.
You can read the 10-Q periodic report (0000014272-24-000147) directly on SEC EDGAR. The filing index links above go to sec.gov.